epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-405, Phase III. Recruiting
A rare inherited neuromuscular disorder (genetically confirmed)
TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.
When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.
Study and plan
Tailspin Rare Diseases (fictional), Phase III, Rare disease. Month 0 is September 2024.
Randomise 64 (drop-out 15%) and screen about 146 (screen failure 56%)
Mar 2027
Confidence wanted
Sites per countryEdit the site counts in the table below
How much sites differSpread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
Central finish (P50)Aug 2030month 71.4
Fast case (P10)Jan 2029month 52.5
Slow case (P90)Not reachedwithin eight years
Chance of meeting the deadline0%wanted 85%
Sites1819% likely to recruit nobody
Patients to screen146to randomise 64
Likely to finish in August 2030, 41 months after the deadline
EPI-405, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far
Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
Month
Fast case
Central
Slow case
Actual
Sep 2024
0
0
0
0
Mar 2025
0
0
0
0
Sep 2025
4
2
0
1
Mar 2026
12
7
3
4
Sep 2026
21
13
7
7
Mar 2027
30
20
12
–
Sep 2027
39
26
16
–
Mar 2028
48
32
20
–
Sep 2028
57
39
24
–
Mar 2029
64
45
28
–
Sep 2029
64
51
33
–
Mar 2030
64
58
37
–
Sep 2030
64
64
41
–
Mar 2031
64
64
45
–
Sep 2031
64
64
49
–
Mar 2032
64
64
54
–
Sep 2032
64
64
58
–
Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.
How likely is it to finish by a given month?
Almost no chance of finishing by March 2027
Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 0 of 100 dots finish in time
Drag the handle or
In time: 0%Median Aug 2030 · 15 dots not complete by Sep 2032Late: 100%
Source: epiClinical Poisson-gamma simulation
Show data
Chance that recruitment is complete by the end of each month
Month
Chance complete by then
Sep 2024
0%
Mar 2025
0%
Sep 2025
0%
Mar 2026
0%
Sep 2026
0%
Mar 2027
0%
Sep 2027
0%
Mar 2028
2%
Sep 2028
5%
Mar 2029
13%
Sep 2029
24%
Mar 2030
38%
Sep 2030
51%
Mar 2031
63%
Sep 2031
72%
Mar 2032
79%
Sep 2032
85%
Countries
Use
Country
Patients per site per month
Sites open between
Cap
Sites
Patients by finish
United States
0.048
Therapeutic area: 0.100 Rare disease baseline
Country: ×0.75 United States
Site type: ×0.991 Usual mix in United States, leaning to academic sites
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×1 Standard ×1
Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
Competing trials: ×1.1 None ×1.1
month 6.0 to 12.1
100
17
United Kingdom
0.054
Therapeutic area: 0.100 Rare disease baseline
Country: ×0.85 United Kingdom
Site type: ×0.985 Usual mix in United Kingdom, leaning to academic sites
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×1 Standard ×1
Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
Competing trials: ×1.1 None ×1.1
month 5.9 to 11.9
44
13
Spain
0.064
Therapeutic area: 0.100 Rare disease baseline
Country: ×1 Spain
Site type: ×0.987 Usual mix in Spain, leaning to academic sites
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×1 Standard ×1
Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
Competing trials: ×1.1 None ×1.1
month 9.5 to 15.5
71
11
Poland
0.092
Therapeutic area: 0.100 Rare disease baseline
Country: ×1.4 Poland
Site type: ×1.02 Usual mix in Poland, leaning to academic sites
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×1 Standard ×1
Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
Competing trials: ×1.1 None ×1.1
month 13.0 to 19.0
41
10
Turkey
0.063
Therapeutic area: 0.100 Rare disease baseline
Country: ×1 Turkey
Site type: ×0.981 Usual mix in Turkey, leaning to academic sites
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×1 Standard ×1
Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
Competing trials: ×1.1 None ×1.1
month 7.9 to 13.9
18
4
India
0.069
Therapeutic area: 0.100 Rare disease baseline
Country: ×1.1 India
Site type: ×0.967 Usual mix in India, leaning to academic sites
Track record: ×0.98 Expected mix for mostly repeat sites
Protocol and population: ×1 Standard ×1
Patient acceptability: ×0.6 Placebo or no added treatment ×0.75, Blinded ×0.8, Heavier than typical ×0.8, Yes ×1.1
Competing trials: ×1.1 None ×1.1
month 7.9 to 13.9
15
8
Country risks to weigh when choosing sites
United States
Two sourced risks
All sites
The first US site opens quickly, but the rest of the US sites open slowly.
The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B
Tightens: site activation overdue
All sites
Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.
Racial and ethnic under-representation · PB-12 · grade A
United Kingdom
Two sourced risks
Some sites
Costing and contracting were the longest start-up step; the national contract has shortened it.
Fragmented, negotiated costing and contracting · POL-03 · grade A
If it recurs
The regulator's backlog of 2023 was cleared, but could recur.
Regulator assessment backlog · POL-02 · grade A
Spain
Two sourced risks
All sites
Site contracts took 117 days in 2016 and about 90 after national templates.
Fragmented, negotiated costing and contracting · POL-03 · grade A
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
Poland
Two sourced risks
All sites
Applications go through the EU Clinical Trials Regulation and its portal.
Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A
All sites
A central ethics committee reviews every study; its effect on timelines is not measured.
Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B
Turkey
Four sourced risks
All sites
Ethics committees fell from 145 to 49 in 2024, cutting review capacity.
Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B
Tightens: site activation overdue
All sites
A fixed pharmaceutical exchange rate has caused repeated medicine shortages.
Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D
Tightens: study drug at the site
All sites
Start-up time has not been measured since CRO data from 2014 and 2015.
Start-up time for India and Turkey is unmeasured · PM-04 · grade C
If it recurs
Sites in the south-east lie in the 2023 earthquake zone.
Major earthquake in a site region · SH-11 · grade C
India
Two sourced risks
All sites
Vulnerable participants in trials of new drugs need an audio-visual record of their consent.
Mandatory audio-visual consent for all participants · RW-03 · grade C
Tightens: consent findings
All sites
Start-up time is unmeasured beyond the statutory 90 working days.
Start-up time for India and Turkey is unmeasured · PM-04 · grade C
Tightens: site activation overdue
Risk-register entries; the choice of entries per country is epiClinical's.